Abstracts

Application of the Geenius™ HIV1/2 Supplemental Assay for Detection of Recent HIV Infections

Background: Assays that measure evolving biomarkers during HIV seroconversion are being used in cross sectional studies for HIV incidence estimation. The Bio-Rad Geenius™ HIV 1/2 Supplemental Assay has been developed for HIV-1 and HIV-2 antibody (Ab) confirmation and differentiation. It is a rapid (30 minute), immunochromatographic test that utilizes serum, plasma, finger stick or whole…

Cost Effectiveness of Adding 4th-Generation Immunoassay Screening After a Negative Rapid HIV Test

Background: While point-of-care rapid HIV tests are essential to HIV prevention services in high-risk communities, these assays may not detect early HIV infection. We evaluated the cost-effectiveness of using 4th generation lab-based immunoassay (4G IA) following a negative rapid HIV test to screen for early infection. Methodology: A published mathematical model was used to estimate…

Performance of HIV Rapid Tests to Identify Seroconverters in MTN 003 (VOICE)

Background: Accurate and efficient identification of seroconverters in antiretroviral-based HIV prevention trials is critical for minimizing emergence of resistance. The use of second-generation (IgG) HIV-1 rapid tests followed by confirmation by Western blot and/or HIV-1 RNA is the most common strategy to identify seroconverters in HIV prevention studies. We evaluated 150,125 HIV rapid tests performed…

Evaluation of the Proposed US CDC Algorithm for Detection of Acute HIV Infection in Serial Samples

Background: A new HIV diagnostic algorithm has been proposed by the US CDC to improve acute HIV infection (AHI) detection and type differentiation of anti-HIV-1 from HIV-2 antibodies. The algorithm employs a 4th generation HIV-1/2 ELISA (4th gen) followed by the Multispot HIV-1/HIV-2 Rapid Test and nucleic acid testing, if indicated. We evaluated algorithm performance…

HIV in People Who Use Drugs

Background: Despite ample evidence of the effectiveness of several interventions to prevent HIV among people who use drugs, the global goal of reducing transmission by 50% by 2015 is not likely going to be achieved. Coverage of these key interventions such as needle and syringe programs and medically assisted therapy remain low particularly in low…

CNS Outcomes of cART vs. cART plus Maraviroc and Raltegravir Intensification During Acute HIV

Background: Within weeks of HIV infection, HIV RNA is found in cerebrospinal fluid (CSF) with accompanying changes in brain parenchyma by magnetic resonance spectroscopy (MRS) supporting theories of early CNS seeding with virus. Intensification of cART with CCR5 and integrase inhibitors is strategized to limit HIV reservoirs when instituted early after HIV infection. The impact…

CSF Viral Escape in Patients Without Neurological Disorders: Prevalence and Associated Factors

Background: CSF viral escape (CVE) is an emerging issue in the HIV setting and has been associated with neurologic symptoms and neurocognitive impairment. Few studies have estimated CVE prevalence and factors associated. Methodology: Single-center retrospective study on CSF/plasma paired samples obtained from HIV-patients undergoing spinal tap because of neurologica signs/symptoms or CNS stage of systemic…